Research Analysts Set Expectations for Glaukos Q1 Earnings

Glaukos Co. (NYSE:GKOS - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Glaukos in a research report issued to clients and investors on Thursday, May 1st. William Blair analyst M. Andrew anticipates that the medical instruments supplier will post earnings per share of ($0.09) for the quarter. The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. William Blair also issued estimates for Glaukos' Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.06 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.19 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same period in the previous year, the firm earned ($0.70) earnings per share. Glaukos's quarterly revenue was up 24.6% compared to the same quarter last year.

GKOS has been the subject of a number of other research reports. Morgan Stanley lowered their price target on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a report on Tuesday. Stephens decreased their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday. Piper Sandler dropped their target price on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. Truist Financial restated a "buy" rating and issued a $135.00 price target (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Finally, Stifel Nicolaus reduced their price objective on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Glaukos currently has an average rating of "Moderate Buy" and an average target price of $133.92.

Glaukos Trading Up 0.7 %

GKOS stock traded up $0.64 during trading on Monday, hitting $87.50. The company had a trading volume of 760,837 shares, compared to its average volume of 676,499. The firm has a market capitalization of $4.99 billion, a P/E ratio of -30.49 and a beta of 0.88. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos has a 52-week low of $77.10 and a 52-week high of $163.71. The company has a 50 day simple moving average of $96.31 and a 200-day simple moving average of $128.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GKOS. State of Wyoming lifted its stake in shares of Glaukos by 2.3% in the fourth quarter. State of Wyoming now owns 3,245 shares of the medical instruments supplier's stock worth $487,000 after buying an additional 72 shares in the last quarter. Quadrant Capital Group LLC boosted its holdings in shares of Glaukos by 3.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after purchasing an additional 73 shares during the last quarter. Mutual of America Capital Management LLC grew its position in shares of Glaukos by 1.1% in the fourth quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier's stock valued at $1,252,000 after purchasing an additional 89 shares in the last quarter. HighTower Advisors LLC increased its holdings in shares of Glaukos by 2.8% in the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier's stock valued at $495,000 after purchasing an additional 91 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its position in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier's stock worth $4,003,000 after buying an additional 100 shares in the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Glaukos

In related news, insider Tomas Navratil sold 3,416 shares of the company's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company's stock, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Alex R. Thurman sold 1,520 shares of the firm's stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.